Stoke Therapeutics, Inc. (STOK)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Revenue | 13,817 | 158,569 | 4,894 | |
| Research and development | 25,855 | 32,676 | 22,205 | |
| General and administrative | 15,262 | 14,653 | 12,692 | |
| Total operating expenses | 41,117 | 47,329 | 34,897 | |
| Income (loss) from operations | -27,300 | 111,240 | -30,003 | |
| Other income (expense), net | 28 | 28 | 28 | |
| Interest income (expense), net | 3,789 | 2,889 | 3,545 | |
| Total other income (expense) | 3,817 | 2,917 | 3,573 | |
| Income (loss) before income taxes | -23,483 | 114,157 | - | |
| Provision for income taxes | - | 1,278 | - | |
| Net income (loss) | -23,483 | 112,879 | -26,430 | |
| Unrealized gain (loss) on marketable securities | 200 | 47 | 181 | |
| Total other comprehensive gain (loss) | 200 | 47 | 181 | |
| Comprehensive income (loss) | -23,283 | 112,926 | -26,249 | |
| Earnings per share, basic, total | -0.4 | 1.95 | -0.47 | |
| Earnings per share, diluted, total | -0.4 | 1.9 | -0.47 | |
| Weighted average number of shares outstanding, basic, total | 58,353,855 | 57,862,674 | 56,341,074 | |
| Weighted average number of shares outstanding, diluted, total | 58,353,855 | 59,398,600 | 56,341,074 | |